Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sebastian Bauer; Robin L. Jones; Jean Yves Blay; Hans Gelderblom; Suzanne George; Patrick Schöffski; Margaret von Mehren; John Zalcberg; Yoon‐Koo Kang; Albiruni Abdul Razak; Jonathan C. Trent; Steven Attia; Axel Le Cesne; Ying Su; Julie Meade; Tao Wang; Matthew L. Sherman; Rodrigo Ruiz‐Soto; Michael C. Heinrich

doi:10.1200/jco.22.00294

Related publications

Article2024

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

John Zalcberg, Robin L. Jones, Jean Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Erika Davis, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich

Article2024

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, César Sánchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta Somaiah, Ping Chi, William M. Reichmann, Kam Sprott,

Article2023

Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Robin L. Jones, Jean Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, William M. Reichmann, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich

Article2023

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.

Sebastian Bauer, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, William M. Reichmann, Kam Sprott, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Jean Yves Blay, Michael C. Heinrich

Article2022

Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.

Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, B. Harrow, Claus Becker, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer